🟡 Preliminary Evidence
A plasma proteomics analysis of 15,012 postmenopausal women from UK Biobank reveals that earlier menopause is associated with accelerated aging biomarkers in brain tissue, challenging decades of dismissal of menopausal cognitive symptoms as purely psychological. The finding, published as a preprint by Alexander et al. (2026) on Research Square, showed that women with earlier menopause had elevated markers of inflammation and brain aging, with replication in an independent cohort of 1,210 women from the Women’s Health Initiative Long Life Study.
Key takeaways
- Earlier menopause was associated with accelerated brain and oligodendrocyte aging on proteomic clocks, as measured by Alexander et al. (2026) in UK Biobank
- The protein GDF15—a known aging marker—showed the strongest single correlation with menopause timing in the cohort
- Brain aging signatures correlated with four clinical outcomes: incident dementia risk, brain atrophy, cerebral small vessel disease, and white matter integrity decline
- The finding replicated in an independent women’s cohort, strengthening confidence in the observational result, though causation remains unproven
Study at a Glance
| Source | Research Square (preprint) |
| Study type | Observational plasma proteomics cohort analysis |
| Primary cohort | N = 15,012 postmenopausal women |
| Replication cohort | N = 1,210 women (Women’s Health Initiative Long Life Study) |
| Countries | United Kingdom (UK Biobank); United States (WHI) |
Menopause Timing and Proteomic Aging Signals
Earlier menopause associated with accelerated brain aging clocks and pro-inflammatory pathways, UK Biobank cohort (Alexander et al., 2026)
Source: Alexander et al., 2026, Research Square | Georgian Medical Journal News
Decades of Dismissal: From Symptoms to Biomarkers
Women reporting cognitive symptoms during and after menopause—brain fog, memory lapses, difficulty concentrating—have historically been told the cause was stress, poor sleep, or simple aging. The new analysis by Alexander et al. (2026) published on Research Square suggests the biological reality is more complex. The researchers measured 4,700 circulating proteins in blood plasma and correlated them with age at menopause, finding a signature pattern: earlier menopause correlated with upregulation of pro-inflammatory pathways and extracellular matrix degradation—hallmarks of accelerated tissue aging.
The signal extended beyond general aging markers. When the researchers applied brain-specific aging clocks—computational models trained on proteomic data to estimate biological age of brain tissue—women with earlier menopause showed acceleration of those clocks. The same pattern appeared for oligodendrocyte aging clocks, relevant to white matter health. This adds biological credibility to decades of anecdotal reports from women whose cognitive symptoms were previously attributed to psychosocial factors. See our Clinical Updates section for more on emerging menopause research.
Earlier menopause was associated with elevated proteomic markers of inflammation and accelerated brain aging clocks, with downstream associations to dementia risk, brain atrophy, cerebral small vessel disease, and white matter microstructural decline.
— Alexander et al., Research Square preprint (2026)
GDF15: A Protein at the Intersection of Aging and Menopause
Among thousands of measured proteins, one emerged with the strongest single correlation to menopause timing: growth differentiation factor 15 (GDF15). The authors describe GDF15 as a canonical aging marker—a protein repeatedly associated with aging trajectories and age-related diseases across multiple independent studies. Higher circulating GDF15 in Alexander et al.’s analysis correlated with earlier menopause age. The full menopause-associated protein signature—the whole constellation of inflammatory and matrix-degradation proteins—then showed concordant associations with four downstream brain outcomes measured in the same UK Biobank cohort: incident dementia risk, brain atrophy, cerebral small vessel disease burden, and white matter microstructural integrity decline. This suggests a possible mechanistic link, though the study cannot prove causation.
The replication in an independent cohort strengthens the finding considerably. When Alexander et al. tested their protein signature in 1,210 postmenopausal women from the Women’s Health Initiative Long Life Study, the same associations held—a critical quality marker for observational proteomics research, which can be prone to spurious correlations in large datasets.
Important Caveats: What This Study Does and Doesn’t Show
This is a preprint, not yet peer-reviewed. The data is observational, showing correlation between menopause timing and brain aging biomarkers, not causation. The brain aging clocks themselves are research tools derived from proteomic data—they are not validated clinical diagnostics that can be applied to individual patients. The findings do not prove that early menopause causes brain aging; they show an association that invites further investigation.
The study also cannot distinguish between direct hormonal effects of menopause on the brain and confounding factors (genetics, lifestyle, metabolic health, other medical conditions) that might influence both menopause timing and brain aging independently. Future research using experimental designs—potentially including randomized controlled trials of hormone therapy in specific high-risk groups—would be needed to test causality. See our New Studies section for ongoing clinical trial updates in women’s health.
What this means
What Happens Next: Research Directions
The next phase of research will likely focus on mechanism: Does estrogen or other hormonal changes directly accelerate brain aging, or do systemic inflammatory and vascular changes triggered by menopause indirectly affect the brain? Prospective studies with repeated proteomic sampling around the menopause transition could clarify timing and causality. Clinical trials of hormone replacement therapy or other interventions in women with early menopause, stratified by these new proteomic markers, could test whether modifying inflammation reduces dementia risk. The UK Biobank and WHI cohorts have longitudinal follow-up data that may permit survival analysis linking these proteomic signatures to long-term clinical outcomes.
Frequently asked questions
Does this study prove that early menopause causes brain aging?
No. The study shows association, not causation. It is observational, meaning the researchers measured proteins and menopause age at a single or limited time points, then looked for correlations. Causation would require experimental evidence, such as animal studies showing direct hormonal effects or randomized trials of hormone therapy showing cognitive benefit in early menopause.
Should I be worried if my menopause started before age 45?
Early menopause (before 45) or premature menopause (before 40) carries risks for cardiovascular disease, bone loss, and possibly cognitive decline. This new study adds to that evidence. Discuss your menopause age and any cognitive symptoms with your doctor, who can assess individual risk and recommend screening or preventive measures appropriate for you.
Can I use these brain aging clocks to check my own brain age?
These brain aging clocks are research tools, not clinical diagnostic tests. They are derived from large datasets and measure proteomic patterns, but they have not been validated for individual clinical use. Your physician cannot use these clocks to diagnose your brain age. Clinical cognitive testing and structural brain imaging remain the standard diagnostic approaches.
As research into menopause biology accelerates, the dismissal of menopausal cognitive symptoms as psychosomatic becomes increasingly untenable. Alexander et al.’s finding—that earlier menopause correlates with accelerated proteomic brain aging and elevated dementia risk—shifts the burden of proof onto clinicians and researchers to explain the mechanism and explore whether early intervention could modify the trajectory. Large prospective studies and clinical trials in this population are now overdue.
Source: Alexander et al., 2026, Research Square
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
